Results 191 to 200 of about 107,195 (244)

The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair. [PDF]

Int Wound J
Nahm WJ, Falanga V.
europepmc   +1 more source

Cardiac PAD2 expression and myocardial citrullination decline with age in female mice independent of estrogen. [PDF]

Am J Physiol Heart Circ Physiol
Shorthill SK, Klinger FR, Yusifov A, Thornburg JP, Schmitt MP, Mehl ER, Bettadapura SS, Agor MH, Teulé-Finley F, Cherrington BD, Bruns DR.   +10 more
europepmc   +1 more source

Anti-endothelial cell antibodies in pathogenesis of vasculitis. [PDF]

Front Immunol
Zhang T, Li L, Huang S, Starodubtseva MN, Liu J.   +4 more
europepmc   +1 more source

Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer. [PDF]

Ann Med Surg (Lond)
Rais T, Shakeel A, Naseem L, Nasser N, Aamir M.   +4 more
europepmc   +1 more source

PHLPP1 regulates region-specific astroglial mitochondrial fission in response to oxidative stress in the male rat hippocampus. [PDF]

Sci Rep
Kim JE, Wang SH, Kang TC.
europepmc   +1 more source

Pan-TRK positive uterine sarcoma in immunohistochemistry without neurotrophic tyrosine receptor kinase gene fusions: A case report.

World J Clin Cases
Lee S, Jeon YR, Shin C, Kwon SY, Shin S.
europepmc   +1 more source

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Journal of Medicinal Chemistry, 2016
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of ...
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, R Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo, Luca Corti, Daniele Donati, Marina Fasolini, Eduard Felder, Claudio Fiorelli, Francesco Fiorentini, Arturo Galvani, Antonella Isacchi, Andrea Borgia, Chiara Marchionni, M. Nesi, Christian Orrenius, Achille Panzeri, Enrico Pesenti, Luisa Rusconi, Maria Beatrice Saccardo, Ermes Vanotti, Ettore Perrone, Paolo Orsini   +28 more
semanticscholar   +4 more sources

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

European Journal of Medicinal Chemistry, 2022
Tropomyosin receptor kinases (TRKs) are a family of TRKA, TRKB and TRKC isoforms. It has been widely reported that TRKs are implicated in a variety of tumors with several Pan-TRK inhibitors currently being used or evaluated in clinical treatment. However, off-target adverse events frequently occur in the clinical use of Pan-TRK inhibitors, which result
Zhijie Wang, Jiwei Ren, Kun Jia, Yuming Zhao, Li Liang, Zitian Cheng, Fei Huang, Xiaofei Zhao, Jie Cheng, Shiyu Song, Tiancheng Sheng, Weiqi Wan, Qingqing Shu, Donglin Wu, Junhao Zhang, Tao Lu, Yadong Chen, Ting Ran, Shuai Lü   +18 more
openalex   +3 more sources

Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma

Human Pathology, 2013
Members of the tropomyosin receptor kinase (Trk) family have a high affinity for neurotrophins and regulate neuronal survival. The role of Trks in cancer is still controversial. The expression and role of TrkB and TrkC were examined in colorectal cancer (CRC). Immunohistochemical analysis of TrkB and TrkC was performed in 133 patients with CRC.
Tomonori Sasahira, N. Ueda, Miyako Kurihara, Sayako Matsushima, Hitoshi Ohmori, Kiyomu Fujii, Ujjal K. Bhawal, Kazuhiko Yamamoto, Tadaaki Kirita, Hiroki Kuniyasu   +9 more
openalex   +4 more sources